Lundi, 6 Juillet 2020
Dernières nouvelles
Principale » DexCom, Inc. (DXCM) Given "Buy" Rating at Canaccord Genuity

DexCom, Inc. (DXCM) Given "Buy" Rating at Canaccord Genuity

14 Juin 2017

Corporate insiders own 1.70% of the company's stock. (NASDAQ:DXCM) to report earnings on August, 1. State Street Corp boosted its stake in shares of DexCom by 39.7% in the fourth quarter. Canaccord Genuity reissued a "buy" rating and set a $90.00 target price on shares of DexCom in a report on Wednesday, June 7th. The stock has "Buy" rating by BTIG Research on Monday, October 31. Jefferies Group LLC lifted their price target on shares of DexCom from $80.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, March 1st. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $78.00 price target on shares of DexCom in a research report on Monday, May 22nd.

Among 3 analysts covering Conifex Timber (TSE:CFF), 1 have Buy rating, 0 Sell and 2 Hold. The company presently has an average rating of "Buy" and a consensus price target of $90.44.

DexCom, Inc. (NASDAQ:DXCM)'s RSI (Relative Strength Index) is 58.53. The firm's market capitalization is $6.34 billion.

Over the past 50 days, DexCom, Inc. stock was -14.14% off of the high and 11.18% removed from the low. (NASDAQ:DXCM) were released by: "Medgadget.com and their article: "Global Market Analysis Report On DexCom Inc (DXCM) â€" Product Pipeline, 2017 Update" published on June 13, 2017 as well as Businesswire.com's news article titled: "DexCom Announces FDA Approval of G5 Mobile App for Android Devices" with publication date: "June 07, 2017. The medical device company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The institutional investor held 17,769 shares of the health care company at the end of 2016Q4, valued at $1.06 million, up from 12,102 at the end of the previous reported quarter. Analysts anticipate that DexCom, Inc. will post ($0.70) EPS for the current fiscal year. Daiwa Securities Group Inc. raised its stake in DexCom by 475.0% in the first quarter. The firm has "Buy" rating by Deutsche Bank given on Friday, July 15. If you are reading this story on another website, it was illegally copied and reposted in violation of worldwide trademark and copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/06/13/massachusetts-financial-services-co-ma-raises-position-in-dexcom-inc-dxcm.html. The scale is 1 to 5 where a Strong Buy rating is a 1 sliding down to a Strong Sell rating for a 5. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the firm's stock in a transaction on Friday, March 17th. The shares were sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares of the company's stock, valued at approximately $4,943,854.55. The disclosure for this sale can be found here. Insiders sold a total of 61,595 shares of company stock valued at $4,571,301 over the last quarter.

Trump partially denies Comey's testimony, mum on existence of recordings
Trump said Friday that he'd be willing to testify under oath "one hundred percent". "I hardly know the man", he said. Former FBI boss Bob Mueller has been appointed as a special counsel to oversee the Russian Federation investigation.

Several other hedge funds have also made changes to their positions in DXCM.

Old National Bancorp increased its stake in Dexcom Inc (DXCM) by 46.83% based on its latest 2016Q4 regulatory filing with the SEC. The Advisors Asset Management Inc holds 492,544 shares with $9.32M value, up from 347,245 last quarter.

Dexcom, Inc.is a medical device company. Mn Services Vermogensbeheer B.V. raised its stake in DexCom by 3.8% in the first quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company's stock worth $526,418,000 after buying an additional 84,085 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in shares of DexCom by 6.3% in the fourth quarter. Legal & General Group Plc now owns 76,054 shares of the medical device company's stock worth $6,444,000 after buying an additional 26,579 shares in the last quarter.

Dexcom, Inc (Dexcom) is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers.